If you can afford the average cost of health care as you age, you'll be closer to solving one of the thorniest problems in retirement planning. When it comes to bills in retirement, health care isn’t ...
Abstract: The subcutaneous mechanical response of the fingertip is highly anisotropic due to the presence of a network of collagen fibers linking the outer skin layer to the bone. The impact of this ...
A 35-year-old man presented with a two-year history of dry cough and progressive dyspnea that had recently worsened. He had been using marijuana since he was 11 years old. Chest CT revealed a single ...
OAK BROOK, Ill. – Emphysema detected on baseline low-dose chest CT (LDCT) in the lung cancer screening cohort of more than 9,000 asymptomatic adults was associated with death from all causes, chronic ...
The median total clinic time was not significantly shorter for patients who received subcutaneous trastuzumab/pertuzumab than for those who received the intravenous ...
The final, formatted version of the article will be published soon. Objective: Lung diseases that are chronic (emphysema [EMP], airway disease, interstitial lung disease) can complicate rheumatoid ...
Leqembi Iqlik is expected to be launched on October 6, 2025. The Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Leqembi ® Iqlik ™, a once weekly ...
STOCKHOLM, Sept. 3, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have initiated a rolling submission of the Supplemental Biologics ...
The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous (IV) phase. Leqembi Iqlik is a subcutaneous ...
Leqembi Iqlik's subcutaneous injection for Alzheimer's disease received FDA approval, based on Phase III trial data showing comparable efficacy to IV dosing. The subcutaneous formulation demonstrated ...
The FDA has approved a subcutaneous formulation of lecanemab (Leqembi Iqlik, Eisai/Biogen) for maintenance dosing in patients with Alzheimer’s disease (AD) with mild cognitive impairment (MCI) or mild ...
Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback